Arcellx Inc
NASDAQ:ACLX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (44.5), the stock would be worth $17.12 (85% downside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 299.1 | $115.07 |
0%
|
| 3-Year Average | 44.5 | $17.12 |
-85%
|
| 5-Year Average | 44.5 | $17.12 |
-85%
|
| Industry Average | 6.7 | $2.59 |
-98%
|
| Country Average | 2.4 | $0.94 |
-99%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
$6.6B
|
/ |
Jan 2026
$22.3m
|
= |
|
|
$6.6B
|
/ |
Dec 2026
$98.6m
|
= |
|
|
$6.6B
|
/ |
Dec 2027
$266.9m
|
= |
|
|
$6.6B
|
/ |
Dec 2028
$455.1m
|
= |
|
|
$6.6B
|
/ |
Dec 2029
$770.9m
|
= |
|
|
$6.6B
|
/ |
Dec 2030
$1.1B
|
= |
|
|
$6.6B
|
/ |
Dec 2031
$1.3B
|
= |
|
|
$6.6B
|
/ |
Dec 2032
$1.5B
|
= |
|
|
$6.6B
|
/ |
Dec 2033
$1.8B
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
A
|
Arcellx Inc
NASDAQ:ACLX
|
6.7B USD | 299.1 | -29.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
349.5B USD | 5.7 | 83.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
183B USD | 5 | 23.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
160.4B USD | 5.5 | 18.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 9.1 | 27.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.3B USD | 5.4 | 17.2 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 11.6 | 37.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.1B AUD | 2.7 | 29.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.2 |
| Median | 2.4 |
| 70th Percentile | 4.1 |
| Max | 4 613 274.2 |
Other Multiples
Arcellx Inc
Glance View
In the bustling landscape of biotechnology, where innovation is the keystone of success, Arcellx Inc. charts an intriguing path. It operates at the cutting edge of medical science, specializing in the development of engineered immunotherapies for the treatment of cancer and other serious diseases. The company's core technology pivots around its proprietary ARC-SparX platform, a modular antibody-recruiting platform designed to enhance the targeting and activation of T-cells against malignant cells. By engineering these immune cells to specifically recognize and attack cancer, Arcellx endeavors to transcend the traditional boundaries of oncology treatment, offering a more personalized and effective therapeutic approach. Arcellx's financial engine is powered by the potential success of its therapies in development, as well as strategic partnerships and licensing agreements. In the biopharma realm, revenue generation often hinges on the successful progression of clinical trials and the eventual approval and commercialization of its products. For Arcellx, this means advancing its pipeline through rigorous clinical phases while also engaging in collaborations with larger pharmaceutical entities. These partnerships not only offer monetary infusions but also extend the reach of Arcellx's innovative therapies, thus amplifying their commercial potential. Through this strategic blueprint, Arcellx positions itself to capture a share of the lucrative oncology market, all while endeavoring to revolutionize patient care through its scientific innovations.
